3025 related articles for article (PubMed ID: 29485071)
21. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
Aoyama H; Tago M; Shirato H;
JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.
Kiess AP; Wolchok JD; Barker CA; Postow MA; Tabar V; Huse JT; Chan TA; Yamada Y; Beal K
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):368-75. PubMed ID: 25754629
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract][Full Text] [Related]
24. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis.
Prabhu RS; Press RH; Patel KR; Boselli DM; Symanowski JT; Lankford SP; McCammon RJ; Moeller BJ; Heinzerling JH; Fasola CE; Asher AL; Sumrall AL; Buchwald ZS; Curran WJ; Shu HG; Crocker I; Burri SH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):459-467. PubMed ID: 28871997
[TBL] [Abstract][Full Text] [Related]
25. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J
J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840
[TBL] [Abstract][Full Text] [Related]
26. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
27. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases.
Vaios EJ; Shenker RF; Hendrickson PG; Wan Z; Niedzwiecki D; Winter SF; Shih HA; Dietrich J; Wang C; Salama AKS; Clarke JM; Allen K; Sperduto P; Mullikin T; Kirkpatrick JP; Floyd SR; Reitman ZJ
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1507-1518. PubMed ID: 38097090
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.
Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N
Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828
[TBL] [Abstract][Full Text] [Related]
30. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases.
Lehrer EJ; Kowalchuk RO; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Harmsen WS; Jones BM; Sharma S; Ahluwalia MS; Sheehan JP; Trifiletti DM
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):858-868. PubMed ID: 36690161
[TBL] [Abstract][Full Text] [Related]
31. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
32. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
[TBL] [Abstract][Full Text] [Related]
33. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
34. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
35. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
[TBL] [Abstract][Full Text] [Related]
36. Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases.
Li YD; Lamano JB; Kaur G; Lamano JB; Veliceasa D; Biyashev D; Kruser T; Bloch O
J Neurooncol; 2019 Jun; 143(2):337-347. PubMed ID: 30982197
[TBL] [Abstract][Full Text] [Related]
37. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
38. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score.
Schaule J; Kroeze SGC; Blanck O; Stera S; Kahl KH; Roeder F; Combs SE; Kaul D; Claes A; Schymalla MM; Adebahr S; Eckert F; Lohaus F; Abbasi-Senger N; Henke G; Szuecs M; Geier M; Sundahl N; Buergy D; Dummer R; Guckenberger M
Radiat Oncol; 2020 Jun; 15(1):135. PubMed ID: 32487100
[TBL] [Abstract][Full Text] [Related]
39. Single fraction stereotactic radiosurgery and fractionated stereotactic radiotherapy provide equal prognosis with overall survival in patients with brain metastases at diagnosis without surgery at primary site.
Ostdiek-Wille GP; Amin S; Wang S; Zhang C; Lin C
PeerJ; 2023; 11():e15357. PubMed ID: 37223122
[TBL] [Abstract][Full Text] [Related]
40. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]